The University of Southampton
University of Southampton Institutional Repository

Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium-insensitive phospholipase A2 gene expression

Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium-insensitive phospholipase A2 gene expression
Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium-insensitive phospholipase A2 gene expression
We have used Affymetrix gene chip technology to look for changes in gene expression caused by a 24 h exposure of rat primary neonatal cardiac myocytes to the cardioprotective agent urocortin. We observed a 2.5-fold down-regulation at both the mRNA and protein levels of a specific calcium-insensitive phospholipase A2 enzyme. Levels of lysophosphatidylcholine, a toxic metabolite of phospholipase A2, were lowered by 30% in myocytes treated with urocortin for 24 h and by 50% with the irreversible iPLA2 inhibitor bromoenol lactone compared with controls. Both 4 h ischemia and ischemia followed by 24 h reperfusion caused a significant increase in lysophosphatidylcholine concentration compared with controls. When these myocytes were pretreated with urocortin, the ischemia-induced increase in lysophosphatidylcholine concentration was significantly lowered. Moreover, co-incubation of cardiac myocytes with urocortin, or the specific phospholipase A2 inhibitor bromoenol lactone, reduces the cytotoxicity produced by lysophosphatidylcholine or ischemia/reperfusion. Similarly, in the intact heart ex vivo we found that cardiac damage measured by infarct size was significantly increased when lysophoshatidylcholine was applied during ischemia, compared with ischemia alone, and that pre-treatment with both urocortin and bromoenol lactone reversed the increase in infarct size. This, to our knowledge, is the first study linking the cardioprotective effect of urocortin to a decrease in a specific enzyme protein and a subsequent decrease in the concentration of its cardiotoxic metabolite.
child, biological, rna, pharmacology, pyrones, cell death, heart, kinetics, cardiac, antagonists & inhibitors, london, cultured, biology, molecular biology, messenger, protein, rats, enzymology, lysophosphatidylcholines, exposure, drug effects, cell survival, gene expression regulation, genetics, models, cells, injuries, enzyme inhibitors, gene expression, health, metabolism, phospholipases a, naphthalenes, myocardial reperfusion injury, cardiotonic agents, corticotropin-releasing hormone, myocytes, down-regulation, animals
0892-6638
2313-2315
Lawrence, K.M.
a07d60f5-d933-4e97-b42d-95e83a3e6bb8
Scarabelli, T.M.
d7868c28-6fbf-42ac-8353-0c5661c0b58f
Turtle, L.
b16d4607-b64a-4d83-9fd1-b04876b2345e
Chanalaris, A.
5edfc575-d0b4-48dc-8eba-6e430e6d39c2
Townsend, P.A.
89300833-c898-4ae1-a3b2-03214c71da52
Carroll, C.J.
9ffa6b9e-6cb8-4c2f-9356-6347428e4aba
Hubank, M.
d13d0fdf-a78b-45ad-8d14-ea1b81af580f
Stephanou, A.
7481e750-c831-488c-936e-842280541517
Knight, R.A.
a48d0c42-7876-4bf9-808b-cfe88d5dfb3c
Latchman, D.S.
d694ae39-32ec-4da7-b024-aebd3ceb6687
Lawrence, K.M.
a07d60f5-d933-4e97-b42d-95e83a3e6bb8
Scarabelli, T.M.
d7868c28-6fbf-42ac-8353-0c5661c0b58f
Turtle, L.
b16d4607-b64a-4d83-9fd1-b04876b2345e
Chanalaris, A.
5edfc575-d0b4-48dc-8eba-6e430e6d39c2
Townsend, P.A.
89300833-c898-4ae1-a3b2-03214c71da52
Carroll, C.J.
9ffa6b9e-6cb8-4c2f-9356-6347428e4aba
Hubank, M.
d13d0fdf-a78b-45ad-8d14-ea1b81af580f
Stephanou, A.
7481e750-c831-488c-936e-842280541517
Knight, R.A.
a48d0c42-7876-4bf9-808b-cfe88d5dfb3c
Latchman, D.S.
d694ae39-32ec-4da7-b024-aebd3ceb6687

Lawrence, K.M., Scarabelli, T.M., Turtle, L., Chanalaris, A., Townsend, P.A., Carroll, C.J., Hubank, M., Stephanou, A., Knight, R.A. and Latchman, D.S. (2003) Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium-insensitive phospholipase A2 gene expression. FASEB Journal, 17 (15), 2313-2315. (doi:10.1096/fj.02-0832fje).

Record type: Article

Abstract

We have used Affymetrix gene chip technology to look for changes in gene expression caused by a 24 h exposure of rat primary neonatal cardiac myocytes to the cardioprotective agent urocortin. We observed a 2.5-fold down-regulation at both the mRNA and protein levels of a specific calcium-insensitive phospholipase A2 enzyme. Levels of lysophosphatidylcholine, a toxic metabolite of phospholipase A2, were lowered by 30% in myocytes treated with urocortin for 24 h and by 50% with the irreversible iPLA2 inhibitor bromoenol lactone compared with controls. Both 4 h ischemia and ischemia followed by 24 h reperfusion caused a significant increase in lysophosphatidylcholine concentration compared with controls. When these myocytes were pretreated with urocortin, the ischemia-induced increase in lysophosphatidylcholine concentration was significantly lowered. Moreover, co-incubation of cardiac myocytes with urocortin, or the specific phospholipase A2 inhibitor bromoenol lactone, reduces the cytotoxicity produced by lysophosphatidylcholine or ischemia/reperfusion. Similarly, in the intact heart ex vivo we found that cardiac damage measured by infarct size was significantly increased when lysophoshatidylcholine was applied during ischemia, compared with ischemia alone, and that pre-treatment with both urocortin and bromoenol lactone reversed the increase in infarct size. This, to our knowledge, is the first study linking the cardioprotective effect of urocortin to a decrease in a specific enzyme protein and a subsequent decrease in the concentration of its cardiotoxic metabolite.

This record has no associated files available for download.

More information

Published date: 16 October 2003
Keywords: child, biological, rna, pharmacology, pyrones, cell death, heart, kinetics, cardiac, antagonists & inhibitors, london, cultured, biology, molecular biology, messenger, protein, rats, enzymology, lysophosphatidylcholines, exposure, drug effects, cell survival, gene expression regulation, genetics, models, cells, injuries, enzyme inhibitors, gene expression, health, metabolism, phospholipases a, naphthalenes, myocardial reperfusion injury, cardiotonic agents, corticotropin-releasing hormone, myocytes, down-regulation, animals
Organisations: Human Genetics, Community Clinical Sciences, Infection Inflammation & Immunity, Medicine

Identifiers

Local EPrints ID: 59974
URI: http://eprints.soton.ac.uk/id/eprint/59974
ISSN: 0892-6638
PURE UUID: af95fa5c-22bd-4bea-9501-48d7c5df3a3d

Catalogue record

Date deposited: 05 Sep 2008
Last modified: 15 Mar 2024 11:18

Export record

Altmetrics

Contributors

Author: K.M. Lawrence
Author: T.M. Scarabelli
Author: L. Turtle
Author: A. Chanalaris
Author: P.A. Townsend
Author: C.J. Carroll
Author: M. Hubank
Author: A. Stephanou
Author: R.A. Knight
Author: D.S. Latchman

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×